비소세포폐암

Safety, immunologic tolerability, and 1-year treatment effect of a cancer vaccine based on universal amphopeptides in patients with refractory advanced non-small cell lung cancer

간암

Efficacy of lenvatinib plus transcatheter chemoembolization as first-line treatment for advanced liver cancer

간암

Pembrolizumab as Second-Line Treatment in Asian Patients with Advanced Liver Cancer

유방암

Risk of contralateral breast cancer in breast cancer patients with inherited cancer gene mutations

유방암

Effectiveness of lenvatinib in combination with pembrolizumab in the treatment of advanced endometrial cancer

췌장암

KRAS-targeted therapies in pancreatic cancer

Other

Zanidatamab, a novel HER2 bispecific antibody, in solid tumor patients with amplified or overexpressed HER2

장암

Targeted therapies for metastatic colorectal cancer patients with KRAS G12C mutations are now available

폐암

Sotorasip: Identified as a novel second- or third-line standard of care for non-small cell lung cancer with KRAS G12C mutations

흑색종

In patients with BRAF-mutated melanoma, nivolumab/ipilimumab followed by dabrafenib/trametinib as second-line therapy in disease progression has a favorable outcome.

비소세포폐암

Safety, immunologic tolerability, and 1-year treatment effect of a cancer vaccine based on universal amphopeptides in patients with refractory advanced non-small cell lung cancer

간암

Efficacy of lenvatinib plus transcatheter chemoembolization as first-line treatment for advanced liver cancer

간암

Pembrolizumab as Second-Line Treatment in Asian Patients with Advanced Liver Cancer

유방암

Risk of contralateral breast cancer in breast cancer patients with inherited cancer gene mutations

유방암

Effectiveness of lenvatinib in combination with pembrolizumab in the treatment of advanced endometrial cancer